Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products
The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world.
Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.
Nanobiotix amended its $2.7 billion licensing deal with Johnson & Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026.
Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.
A lawsuit has been lodged against JPMorgan Chase by its employees, who claim that the company's prescription drug plan consented to pay exorbitant prices for medications.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQSUPN).
When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But are high-yield stocks always the best route for income-focused investors? Let’s break it down.
The market has thrown a tantrum over recent weeks following tariff news and other economic data pointing to a slowing consumer base. While it’s certainly been a turbulent period, several stocks have been able to shake off these market woes.
Two of the Dow Jones Industrial Average's 30 components make for no-brainer buys, while another brand-name member continues to suffer from self-inflicted wounds.
